SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company Oct 25, 2021 07:39AM
SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company Oct 25, 2021 07:39AM
UPDATE: Ladenburg Thalmann Starts Big Cypress Acquisition Corp. (BCYP) at Buy Oct 1, 2021 06:38AM
Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics Jul 15, 2021 07:00AM
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021 Jul 9, 2021 07:00AM


Jun 22, 2021 06:23AM SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition (BCYP)
Jun 22, 2021 06:00AM SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerg
Feb 4, 2021 08:00AM Big Cypress Acquisition Corp. Announces Separate Trading of its Shares of Common Stock and Redeemable Warrants Commencing February 9, 2021
Jan 14, 2021 12:10PM Big Cypress Acquisition Corp. Announces Closing of $115 Million Initial Public Offering, which Includes Full Exercise of the Underwriters' Over-Allotment Option
Jan 11, 2021 04:25PM Big Cypress Acquisition Corp. (BCYP) Prices 10M Unit IPO at $10/Unit